Does the FDA approve Rytelo for low-risk Myelodysplastic Syndromes?
Rytelo (imetelstat) is a telomerase inhibitor approved by the FDA for a specific group of people with low-risk myelodysplastic syndromes (MDS). It is for adults with low- to intermediate-1 risk MDS who need regular red blood cell transfusions (4 or more units over 8 weeks) and who have not responded to, lost response to, or cannot take erythropoiesis-stimulating agents (ESAs). This approval was based on results from the IMerge phase 3 clinical trial, which showed that imetelstat helped many patients become transfusion-independent for a sustained period.
What the research says
The FDA approved Rytelo (imetelstat) in June 2024 for transfusion-dependent anemia in low- to intermediate-1 risk MDS 467. The approval is specifically for patients who require 4 or more red blood cell units over 8 weeks and who have not responded to, have lost response to, or are ineligible for erythropoiesis-stimulating agents (ESAs) 4. This indication is supported by the IMerge phase 3 clinical trial, which demonstrated that imetelstat induced durable transfusion independence in heavily transfused lower-risk MDS patients 67. Common side effects include thrombocytopenia (low platelets), leukopenia (low white blood cells), elevated liver enzymes, and infusion reactions, which are mostly reversible but can rarely be serious 7. Note that other drugs, such as Revlimid (lenalidomide), are also FDA-approved for transfusion-dependent anemia in low- or intermediate-1-risk MDS, but specifically for patients with a deletion 5q abnormality 1. Rytelo is a different option for patients without that specific genetic feature or who have not responded to other treatments.
What to ask your doctor
- Do I have low- to intermediate-1 risk MDS with transfusion-dependent anemia that might qualify me for Rytelo?
- Have I tried or am I eligible for erythropoiesis-stimulating agents (ESAs) before considering Rytelo?
- What are the potential side effects of Rytelo, especially low blood counts and liver enzyme changes, and how would they be monitored?
- How does Rytelo compare to other treatments like lenalidomide (Revlimid) for my specific MDS subtype?
- What is the expected benefit in terms of reducing or stopping blood transfusions, and how long might that take?
This question is drawn from common patient questions about Hematology and answered using cited medical research. We do not provide individualized advice.